We’ve moved (just around the corner) to our own brand new, state-of-the-art facility - so please update your address book with our new details in the footer below.
The pharmaceutical landscape is evolving rapidly with the introduction of platform technologies, often enhanced by machine learning (ML), and Ingenza is one of the few contract, research, development and manufacturing organisations (CRDMOs) to embrace this approach. Ingenza’s inGenius® platform plays a pivotal role in accelerating…
Ingenza recently welcomed Lisa Fraser as the company’s first Senior Project Manager. Lisa brings extensive leadership and project management experience to her new role, and she will no doubt be instrumental in driving Ingenza’s strategic goals and supporting its pioneering work in…
Many COVID-19 vaccines work by presenting fragments of the SARS-CoV-2 spike protein – the receptor-binding domain (RBD) – to the body to generate an immune response. However, newly arising SARS-CoV-2 variants are increasingly able to evade this response due to…
Cell line development is a critical aspect of biotechnology and pharmaceutical research, and plays an important role in Ingenza’s CRDMO services. The process involves establishing and maintaining genetically identical mammalian cells in culture for use in a variety of processes, such…
The biopharmaceutical sector is expanding twice as fast as traditional drug manufacturing, and currently accounts for 20 percent of the pharmaceutical industry.1,2 Biotechnology companies are therefore under increasing pressure to maintain a rapid pace of development, while providing trackable documentation to…
Recombinant protein production is an important technique for generating large quantities of proteins in a variety of pharmaceutical, agricultural and industrial applications. It is widely used in the development and manufacture of drugs – such as insulin, growth factors and…
Managing the key challenges facing human health and the global environment is an increasingly complex task. Fortunately, bioprocessing – the creation of useful products using biological materials, such as microorganisms – holds the potential to address many of these issues…
Dr Leonardo Magneschi is the Head of Molecular Biology at Ingenza. In 2020 he and his team embarked upon a project in conjunction with the University of Oxford and the Centre for Process Innovation (CPI) to rapidly formulate a highly effective vaccine against SARS-CoV-2, the virus responsible for the COVID-19 pandemic. New research published in Science by…
Advances in engineering biology are creating an ever-expanding toolkit and evolving infrastructure that can conceptualise, deliver and scale solutions to address a wide range of biological, chemical and even social problems. As society emerges from a global pandemic, two of the…
Ingenza has undergone significant transformation and growth since its inception in 2003, which would not have been possible without a talented and multifaceted team lending their collective expertise to the development and commercialisation of biobased products. New positions and responsibilities…